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ENGLISH SUMMARY 
Chronic pancreatitis has an annual incidence between 5-10 per. 100.000 which has 
quadrupled through the last 30 years. The pathological changes of the pancreas in 
chronic pancreatitis are characterized by chronic inflammation, fibrosis, 
dilatation/stenosis of the main pancreatic duct and cystic changes. These changes are 
accompanied by loss of both exocrine and endocrine pancreatic parenchyma. The 
advanced stages of chronic pancreatitis are characterized by typical clinical and 
imaging appearances which results in easy diagnosis of the disease. However, the 
challenge remains to identify the disease in the early subclinical stages when the 
morphological changes are mild. Chronic pain is the hallmark symptom of chronic 
pancreatitis but within 5 years of the diagnosis more than 50 % of the patients have 
developed both endocrine and exocrine insufficiency. Chronic pancreatitis is a 
disabling disease with dramatic social and economic consequences for the patients. 
The objective of this PhD thesis was to develop and apply magnetic resonance 
imaging (MRI) techniques for a detailed characterization of pancreatic morphology 
and function in patients with chronic pancreatitis.  Furthermore, we hypothesized that 
these new MRI parameters could be used for characterization of disease mechanisms, 
monitoring disease progression and aid in treatment of patients with chronic 
pancreatitis. 
Data from two studies were collected for this thesis. In study I, our new secretin-
stimulated MRI (s-MRI) protocol and the new semi-automatic application for 
analyses of pancreatic exocrine function were validated in patients with cystic 
fibrosis. In study II, pancreatic morphology and function was characterized in 82 
patients with chronic pancreatitis. The morphological parameters included pancreatic 
gland volume, main pancreatic duct diameter, Cambridge classification, diffusion 
properties in the pancreatic parenchyma as a measure for fibrosis and measurement of 
fatty infiltrations in the parenchyma. The functional parameters were exocrine 
pancreatic function characterized by quantification of pancreatic secretion and 
changes in diffusion properties after secretion-stimulation. 
The main results showed that patients with chronic pancreatitis had a smaller 
pancreatic gland volume, increased fibrosis and fatty infiltrations in the pancreatic 
parenchyma compared to healthy controls. The exocrine pancreatic function (ability 
to produce pancreatic juice after secretin-stimulation) was significantly reduced in 
patients with chronic pancreatitis. Additionally, patients with more advanced stages 
of chronic pancreatitis had smaller pancreatic gland volumes and reduced pancreatic 
exocrine function was associated with reduced quality of life.  
In conclusion, the advanced s-MRI parameters could differentiate between healthy 
controls and patients with chronic pancreatitis. Additionally, some s-MRI parameters 
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were of clinical relevance for severity and disease burden of chronic pancreatitis.        
S-MRI is a safe, non-invasive method for characterization of pancreatic morphology 
and function, and could in the future aid in understanding the complex disease 
mechanism, improve diagnosis and treatment of patients with chronic pancreatitis.         
 
            
 
  
DANSK RESUME 
Kronisk pankreatitis (bugspytkirtelbetændelse) har en årlig incidens på 5-10 per 
100.000 indbyggere, hvilket er firdoblet igennem de sidste 30 år.  De patologiske 
forandringer i pankreas ved kronisk pankreatitis er kendetegnet ved kronisk 
inflammation, fibrose, forsnævring/dilatation af udførselsgangen samt cystedannelse. 
Dette er ledsaget af tab af både eksokrint og endokrint væv. Fremskreden sygdom er 
karakteriseret ved typiske kliniske og billedmæssige fund, som gør den nem at 
diagnosticere. Den største udfordring er at identificere sygdommen i den tidlige 
subkliniske fase hvor de morfologiske forandringer er minimale. Kroniske smerter er 
det dominerende symptom men indenfor 5 år efter diagnosen har over 50 % udviklet 
både eksokrin og endokrin insufficiens med fejlernæring og diabetes. Det er en meget 
invaliderende sygdom med store sociale og økonomiske konsekvenser for patienterne.  
Formålet med dette ph.d. projekt var at udvikle og anvende magnetisk resonans 
billeddannelse (MRI) teknikker til detaljeret kortlægning af pankreas morfologi og 
funktion hos patienter med kronisk pankreatitis. Målet var at disse nye MRI parametre 
kunne bruges til kortlægning af sygdomsmekanismer, monitorering af 
sygdomsudviklingen og forbedring af behandlingen af patienter med kronisk 
pankreatitis.  
Resultater fra to studier blev inkluderet i dette projekt. I første studie blev vores nye 
sekretin-stimulerede MRI (s-MRI) protokol og nye semi-automatisk program til 
analyse af pankreas eksokrine funktion valideret i patienter med cystisk fibrose. I 
andet studie blev pankreas morfologi og funktion kortlagt med s-MRI hos 82 patienter 
med kronisk pankreatitis. De morfologiske parametre var pankreas kirtel-volumen, 
gang-diameter, Cambridge klassificering, diffusionsegenskaber i parenkymet som 
udtryk for fibrosegrad samt måling af fedt infiltration i parenkymet. De funktionelle 
parametre var eksokrine funktion karakteriseret ved kvantificering af pankreas 
sekretionen samt ændringer i diffusionsegenskaber i parenkymet efter secretin-
stimulation. 
Hovedresultaterne viste at patienter med kronisk pankreatitis havde en mindre kirtel 
volumen, øget fibrose og fedtinfiltrering i pankreas parenkymet sammenholdt med de 
raske kontroller. Den eksokrine funktion (evnen til at danne pankres saft efter 
sekretin-stimulering) var også betydeligt nedsat hos patienter med kronisk 
pankreatitis. Vi viste også at patienter med mere fremskredne stadier af kronisk 
pankreatitis havde en mindre kirtel, og at reduceret eksokrin funktion havde en 
sammenhæng med nedsat livskvalitet.  
Det var således muligt for de avancerede s-MRI parametre at skelne mellem raske 
kontroller og kronisk pankreatitis patienter. Ydermere, var enkelte s-MRI parametre 
af klinisk relevans for særligt sværhedsgraden og sygdomsbyrden af kronisk 
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pankreatitis. S-MRI er en sikker, non-invasiv metode til at karakterisere morfologiske 
og funktionelle forandringer i pankreas og kan i fremtiden være med til at forstå 
sygdomsmekanismerne, sikre en forbedret udredning og behandling af patienter med 
kronisk pankreatitis.   
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INTRODUCTION 
The pancreas is a retroperitoneal gland placed behind the stomach and surrounded by 
small intestine, liver, and spleen. Anatomically, it is divided in to the pancreatic head, 
body and tail and has both endocrine and exocrine functions (1). Histologically, the 
endocrine functions are managed by the islet cells that compromise only 2% of the 
normal pancreatic parenchyma, while the exocrine function is handled by ductal and 
acinar cells with secretion of pancreatic juice to the duodenum. Major diseases of the 
pancreas include pancreatic cancer, diabetes mellitus, cystic fibrosis, and pancreatitis. 
Despite significant progress in tools for detecting pancreatic pathology over the past 
decades, a detailed, non-invasive test for combined morphological and functional 
characterization of pancreas is still highly warranted.  
 CHRONIC PANCREATITIS 
Chronic pancreatitis (CP) is a fibro-inflammatory disease characterized by irreversible 
morphological and functional changes in the pancreas (2). The most common cause 
for developing CP is long-term excessive alcohol intake which accounts for about 50 
% of all CP cases in the Western world (3). Other causes include smoking, genetic 
(SPINK1, SPSS1 and CFTR mutations), autoimmune (type 1 and type 2), 
environmental and idiopathic factors (4), Figure 1-1. It affects men more often than 
women, and the mean age of 48.9 (± 15) years for onset of CP was reported in one 
large North American survey (5).  
“Common features of established and advanced CP include pancreatic atrophy, 
fibrosis, pain syndrome, duct distortion and strictures, calcifications, pancreatic 
exocrine and endocrine dysfunction, and dysplasia”, as defined by Whitcomb et al. 
2016 (2), Figure 1-1. It was also stated that not all features are necessary present in 
the individual patient. Additionally, the underlying pathophysiological mechanisms 
for developing these common features of CP are complex and not well understood. 
Identifying the common features is done through clinical assessment (alcohol abuse, 
abdominal pain, steatorrhea), morphological changes based on imaging (computed 
tomography (CT), magnetic resonance imaging (MRI) and ultrasound), and testing 
for exocrine and endocrine insufficiency (6). However, a great challenge in the current 
clinical practice is that these disease characteristics are of relevant for mainly well-
established or advanced CP. This implies that we are currently not able to make an 
accurate diagnosis of early stages of CP. Furthermore, there is no well-established 
diagnostic criteria or disease markers for the early stages of CP which furthermore 
makes the diagnosis of early CP complicated. In clinical practice, CP is mainly 
diagnosed from clinical context (e.g. recurrent acute pancreatitis in heavy alcoholics) 
and relevant symptoms, and confirmed several years later by abnormal duct imaging 
or pancreatic calcifications (7). New non-invasive biomarkers characterizing the early 
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features of CP are highly wanted to identify patients in risk of developing CP, monitor 
disease progressions, develop and evaluate new treatment approaches.   
       
Figure 1-1: Overview of risk factors and common features in chronic pancreatitis 
1.1.1. DISEASE BURDEN IN CHRONIC PANCREATITIS 
The three hallmark clinical features of CP are upper abdominal pain, exocrine 
pancreatic insufficiency, and type 3 diabetes mellitus. Pain is the most dominating 
symptom and present in the 80-90 % of patients during their disease course and its 
treatment remains a major clinical challenge (8). Additionally, pain in CP is associated 
with reduced quality of life and it is the primary cause of hospitalization in most 
patients (9). In USA, rates for ambulatory care visits and hospitalizations for acute 
and chronic pancreatitis combined have increased nearly 62% between 1988 and 2004 
(10). In USA, the estimated health care costs in 2004 was 3.7 billion $, additionally 
the retail cost for prescriptions was roughly 88.6 million $. The pancreatic enzyme 
replacement therapy constituted 84.5% of all the prescriptions, the remaining drug 
were analgesic and antiemetic agents. In addition, these number do not include visits 
at the general practitioners who handle much of the long-term care. CP is further 
complicated by psychiatric comorbidity including anxiety and depression (11). The 
heterogeneous character of the disease affects all aspects of patients’ life: work, 
leisure, travel and relationship (12). Thus, the cumulative disease burden in CP is high 
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and associated with reduced quality of life and increased health resource utilization 
(5). 
1.1.2. EXOCRINE PANCREATIC FUNCTION  
The clinical symptoms of mild exocrine pancreatic insufficiency (EPI) are vague, 
including abdominal bloating and cramping, whereas steatorrhea, weight loss and 
malnutrition develops with more severe EPI (13). The diagnosis of EPI requires the 
documentation of maldigestion, along with evidence that reduced exocrine pancreatic 
function is the cause of maldigestion.  
Direct pancreatic function tests are considered the golden standard for diagnosis of 
EPI (6,14). These tests require intravenous administration of secretin to stimulate 
secretion of pancreatic juice. Secretin is a hormone that under normal psychological 
circumstances is secreted from upper intestinal mucosa after ingestion of a mixed 
meal, and its major effect is secretion of bicarbonate rich fluid from the pancreatic 
ductal cells (15). After secretin stimulation, duodenal intubation is performed to 
collect the pancreatic juice and concentrations of digestive enzymes and bicarbonate 
are measured. In the modern approach, the secretin function test has been combined 
with endoscopic ultrasound where pancreatic juice is collected endoscopically 
(16,17). This also allows a morphological assessment of the pancreas. Unfortunately, 
these invasive test are expensive and cumbersome for the patients, and therefore only 
performed at few specialized centers (18). 
Indirect pancreatic function tests do not require direct hormonal stimulation of the 
pancreas, and include 72-h fecal fat and fecal elastase test. Although 72-h fecal fat 
test is accurate for EPI, it is not feasible in the outpatient setting nor with hospitalized 
patients in pain. It includes 5 days of strict diet, 3 days of cumulative stool collection 
and additional laboratory personal (19). In clinical practice, fecal elastase is the 
simplest non-invasive test for assessing EPI (20). It should be performed on a solid 
stool sample to avoid falsely positive results during e.g. diarrhea. However, the test is 
of little help in diagnosing mild to moderate EPI (21). Both 72-h fecal fat test nor fecal 
elastase cannot independently diagnose CP. Newer methods like 13C-MTG 
triglyceride breath test have reported promising results in diagnosing EPI but are still 
only performed at specialized centers (22). Additionally, none of the indirect 
pancreatic function test can identify patients with mild EPI or in risk for developing 
EPI.  
In summary, a novel, non-invasive and accurate test for EPI with the possibility to 
detect early CP is still highly warranted. 
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 CYSTIC FIBROSIS 
Cystic fibrosis (CF) is caused by a mutation in the gene encoding the CF 
transmembrane conductance regulator (23). This mutation leads to abnormal fluid 
secretion from epithelial cells, causing dysfunction in organ systems including the 
lung, gastrointestinal tract, liver, male reproductive tract and pancreas, which is one 
of the earliest affected organs (24). Dysfunction of pancreatic ductal cells results in 
altered composition of pancreatic juice leading to obstruction of small duct and acini. 
With progression, it is accompanied with inflammation, fibrosis and fatty infiltration 
ending with EPI (25). In CF, 85-90% of the patients have EPI which can be present at 
birth or evolves mainly over the first year of life, although some develop EPI later in 
life (26). Development of severe EPI at young age with established marked reduction 
in pancreatic secretion makes patients with CF an optimal cohort for evaluating new 
methods for assessment of exocrine function and volume output failure in EPI (27). 
Additionally, MRI has gained more interest in CF and could potentially provide 
biomarkers for monitoring EPI and identifying CF patients in risk of developing EPI 
(28).        
 MAGNETIC RESONANCE IMAGING 
The signal measured in MRI arises from the water protons in the body, whether 
located in the intracellular or extracellular space. Since its clinical introduction in the 
1980s, the development of MRI has been fast and its range of clinical applications has 
constantly broadened. Currently, conventional T1- and T2-weighted MRI provides a 
detailed depiction of pancreatic anatomy and structure and has impact on diagnosis 
and treatment of various pancreatic diseases such as pancreatic cancer and acute or 
chronic pancreatitis (29).  
In 1991 Wallner et al. introduced a pancreatic MRI method in which the biliary tracts 
were visualized and the method was named “MR cholangiography” (30). Over the 
following years, the resolution of the images increased which was paralleled by 
reduced acquisition time. This also allowed visualization of the main pancreatic duct 
(MPD), and this improved imaging method was named MRCP (30–34). However, 
visualization of the entire MPD and visualization of side branches or subtle changes 
such as minor strictures of the ducts was still problematic. In 1995 secretin-stimulated 
MRCP (s-MRCP) was described by a Japanese group (35) and in 1997 Matos et al. 
published a paper presenting a method for combined morphological and functional 
evaluation of the pancreas (36). The great value of s-MRCP in evaluating MPD is 
reported in numerous publications and s-MRCP is increasingly employed as the first-
choice examination for detection of detailed MPD pathology (37–40). Additionally, 
various secretin-stimulated MRI approaches for detection of EPI (i.e., bicarbonate 
secretion) have been published and shown promising results when compared to direct 
(e.g. endoscopic secretin tests) and indirect (e.g. the fecal elastase test) pancreatic 
function tests (36,41–44).  
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Besides imaging of simple anatomy and the main pancreatic duct, the technical MRI 
development continuously provides us with new techniques for evaluation of the 
pancreatic parenchyma. Diffusion weighted imaging (DWI) is a well-established MRI 
technique that assess the random diffusion/motion of water protons in the body (45). 
DWI measures microscopic diffusion of intracellular, extracellular and vascular water 
protons, and is quantified by the term apparent diffusion coefficient (ADC) (46). 
Several studies have reported that fibrosis causes diffusion restriction in both liver and 
pancreas, meaning lower ADC values in affected organs compared to healthy (47,48). 
Additionally, dynamic DWI before and after secretion stimulation can be used for 
assessment of pancreatic secretory capacity (48,49).  
Additionally, the Dixon imaging technique for separation of water and fat signal in 
tissue was introduced in 1984 (50). Significant improvement of the original technique 
through the last 2 decades has enabled quantitative measurement of diffuse 
parenchymal fat infiltration in abdominal solid organs (51). Studies in the liver have 
reported that Dixon imaging has good diagnostic accuracy for both mild and 
moderate/severe steatosis compared to histological assessment from liver biopsies 
(52). A recent study in pancreas reported positive correlation with fat signal fraction 
(FSF) assessed with Dixon imaging and degree of pancreatic steatosis in specimens 
after pancreatomy (53).  
In addition to development within MRI, new applications for quantitative image 
analyses are constantly evolving. This has enabled quantitative measurements of 
pancreatic secretin and pancreatic gland volume. However, current applications for 
image analyses are still dependent on time consuming manual segmentation and not 
clinically feasible. Functional MRI with new more automated applications for image 
analyses have the potential revolutionize the field of radiology. In summary, there are 
currently numerous advanced MRI techniques that can characterize pancreatic 
morphology and function. However, relatively little is known about their ability to 
detect CP, their internal relationship and the association to disease burden and other 
clinical features in patients with CP. 
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HYPOTHESIS & AIM 
The overall aim was to investigate pancreatic morphology and function with an 
advanced secretin-stimulated MRI (s-MRI) protocol and provide numerous 
differentiated imaging parameters that could represent important pathological features 
in patients with chronic pancreatitis. We hypothesized that a combination of such 
morphological and functional imaging parameters could provide a non-invasive tool 
for monitoring disease progression and aid the treatment of patients with CP. An 
overview of aims and papers are illustrated in Figure 2-1. 
 
Figure 0-1: Overview of the aims from study I (Cystic fibrosis (CF) patients and 
healthy controls (HC)) and study II (Chronic pancreatitis (CP) patients and HC). 
MRI: magnetic resonance imaging; EST: endoscopic secretin test.  
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Subsequently, to fulfill the overall aim, this thesis contains 4 aims: 
I. To investigate latest developments in s-MRI and the range of clinical 
application in benign pancreatic disorders (paper I).  
• The hypothesis was by reviewing the latest literature that an 
advanced s-MRI protocol can be applied in a clinical setting and 
provide relevant information regarding pancreatic morphology and 
especially exocrine function. 
 
II. To evaluate a s-MRI protocol including a novel semi-automatic application 
for assessment of exocrine pancreatic function against a “gold standard” 
endoscopic secretin test in patients with cystic fibrosis compared to healthy 
controls (paper II). 
• The hypothesis was that s-MRI with a new semi-automatic 
application for quantification of pancreatic secretion could be a 
valid, non-invasive alternative for detection of exocrine pancreatic 
dysfunction when compared to the “gold standard” endoscopic 
secretin test. 
 
III. To investigate pancreatic morphology and exocrine function with the novel 
s-MRI protocol in patients with chronic pancreatitis compared to healthy 
controls (paper III). 
• The hypothesis was that CP patients had morphological changes 
and impaired exocrine pancreatic function compared to HCs, which 
could reflect different aspects of the CP pathophysiology. 
 
IV. To explore the association between pancreatic morphological and functional 
s-MRI parameters, clinical characteristics, and disease burden in patients 
with chronic pancreatitis (paper III + IV).  
• The hypothesis was that the changes in pancreatic morphology and 
exocrine function identified by s-MRI could be used in 
prognostication and monitoring of patients with CP.  
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MATERIAL & METHODS 
 MATERIALS 
Two MRI studies contributed to this thesis. The studies were approved by the local 
Ethics Committees (approval number: REK: 2010/2857-7 (study I) and N-20130040 
& N-20130059 (study II)) and conducted according to the Declaration of Helsinki. 
Informed consent was obtained from both patients and healthy controls (HC) after 
both oral and written information was given.  
1.4.1. STUDY I 
Study I was conducted at the Cystic Fibrosis Clinic, Haukeland University Hospital, 
Bergen, Norway. Nineteenth patients with CF and 10 HC were included. The 
diagnostic criteria for CF was based on the CF foundation consensus report (54). 
Information on CF transmembrane conductance regulator mutation and sweat test 
values were extracted from patient journal as documentation for CF. Healthy controls 
had no previous history of gastrointestinal disease. Secretin-stimulated MRI and 
endoscopic secretin test (EST) was performed on all subjects included in the study. 
Median time between EST and s-MRI was 28 (range 24-38) months for CF patients 
and 24 (range 12-51) months for HC.   
1.4.2. STUDY II  
Study II was conducted from at Centre for Pancreatic Disease, Department of 
Radiology and Department of Gastroenterology & Hepatology, Aalborg University 
Hospital, Denmark. Eighty-two patients with CP and 22 HC were included in the 
study. The diagnosis of CP was based on the Lüneburg criteria and CP was defined as 
a score ≥ 4 points (55). Patients with suspected acute exacerbation of CP were 
excluded. All healthy subjects were screened to exclude any history of pancreas-
related disease or gastrointestinal disease. From November 2013 – February 2015 s-
MRI was performed on all CP patients and HC. From the date of the patients 
individual s-MRI examination to August 2016, data on all CP related hospitalizations 
was collected prospectively. Additionally, data on quality of life (QOL) and pain was 
collected from questionnaires filled out at the outpatient clinic annual exam closest to 
the individual date for s-MRI.           
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 METHODS 
Study I and II were performed at two different hospitals using two different brands of 
MRI scanners (Siemens and General Electric Healthcare) for acquiring the data. 
However, the MRI scanners had the same magnetic field (1.5T) and great efforts were 
made to make the s-MRI protocol sequences as similar as possible. The methods 
including the s-MRI protocols are described in the following section and Figure 3-1 
shows an overview of the two studies.  
 
Figure 3-1: Overview of the study I and study II. Abbreviations: CP: chronic 
pancreatitis; CF: cystic fibrosis; HC: healthy controls; 3D MRCP: 3-dimensional 
magnetic cholangiopancreatography; M-ANNHEIM: M-ANNHEIM clinical staging 
of chronic pancreatitis. 
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1.5.1. SECRETIN-STIMULATED MRI PROTOCOL 
S-MRI was performed on all subjects in supine position after minimum 4 hours of 
fasting. Intravenous administered of secretin (1 CU/kg, maximum dose of 70 CU, 
Secrelux®, Sanochemia Diagnostics, Neuss, Germany) was performed over a period 
of 3 minutes.  
 
For study I, an 1.5T MR scanner (Siemens Healthcare, Erlangen, Germany) was used 
with a 24-channel spine matrix coil and a six-channel body coil. The imaging protocol 
is provided in Table 3-1. 
 
Imaging 
sequence 
Plane TR/TE 
(ms) 
Slice 
thickness 
(mm) 
Matrix Acquisition 
FS T1 VIBE axial 5.4/2.4 2.5 320x221 BH 
T2 TrueFISP axial 2.79/1.17 4 512x205 BH 
DWI axial 1400/70 6.0 192x144 FB 
T2 HASTE coronal 3500/113 10 256x238 BH 
Table 3-1: Secretin-stimulated MRI protocol for study I. All sequences were 
performed before secretin. T2 HASTE and DWI sequences were performed 10 and 4 
minutes before and repeated 1, 5, 9 and 13 minutes after secretin stimulation. Axial 
DWI was performed with b-values 50 and 800 s/mm2. Abbreviations: TR/TE: 
repetition time/echo time; FA VIBE: Fat saturated volume interpolated examination; 
TrueFISP: Balanced steady-state free precession: HASTE: Half-fourier acquisition 
single-shot turbo spin echo; DWI: diffusion weighted imaging; BH: Breath hold; FB 
RTs: Free breathing with respiratory triggering. 
For study II, an 1.5T MR scanner (Signa HDxt, version 23, General Electric 
Healthcare, Milwaukee, Wisconsin, USA) was used with an 8-channel body coil. The 
imaging protocol is provided in Table 3-2.  
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Imaging 
sequence 
Plane TR/TE 
(ms) 
Slice 
thickness 
(mm) 
Matrix Acquisition 
FIESTA axial 3.5/1.5 4.0 256x192 BH 
3D MRCP coronal 3500/630 2.6 320x256 FB RTs 
LAVA-Flex axial 7/4 2.6 320x192 BH 
DWI axial 4000/70 6.0 160x192 FB 
T2 SSFSE coronal 2500/120 10.0 256x224 BH 
Table 3-2: Secretin-stimulated MRI protocol for study II. All sequences were 
performed before secretin. T2 SSFSE and DWI sequences were performed 10 and 4 
minutes before and repeated 1, 5, 9 and 13 minutes after secretin stimulation. Axial 
DWI was performed with b-values 50, 400 and 800 s/mm2. Abbreviations: TR/TE: 
repetition time/echo time; FIESTA: fast imaging employed steady-state acquisition; 
SSFSE FS: Single shot fast spin echo fat saturated: 3D MRCP: 3-dimensional 
magnetic resonance cholangiopancreatography; LAVA-flex: liver acquisition with 
volume acceleration flex; DWI: diffusion weighted imaging; BH: Breath hold; FB 
RTs: Free breathing with respiratory triggering. 
1.5.2. PANCREATIC GLAND VOLUME  
For study I, pancreatic gland volume was measured on axial FS T1 VIBE in the 
commercially available software NordicICE 2.3.12 (NordicNeuroLab, Bergen, 
Norway). Contour of the pancreas was manually segmented on every slice, 
considering each area to represent a volume of 2.5 mm thickness. The areas were 
added to calculate the pancreatic volume.  For study II, gland volume was measured 
on axial FIESTA images in a customized semi-automatic application developed in 
Matlab 2013b (Mathworks, Natick, Massachusetts, USA). The contour of the 
pancreas was also manually segmented on each slice excluding main pancreatic duct 
segments over 3 mm and all cystic lesions, see Figure 3-2A. The application then 
automatically calculated pancreatic gland volume.  
1.5.3. MAIN PANCREATIC DUCT (ONLY STUDY II) 
The maximum diameter of the main pancreatic duct, pathological side branches and 
potential cystic lesions were measured on 3-dimensional MRCP obtained before 
secretin administration using commercially available software (EazyViz v. 7.2.6, 
Karos Health A/S, Valby, Denmark), see Figure 3-2B.  
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1.5.4. CAMBRIDGE CLASSIFICATION (ONLY STUDY II) 
The original Cambridge classification was limited to duct visualization via endoscopic 
retrograde pancreatography with an expansion to include CT and ultrasound (56). For 
our studies we used a MRI adaption of the Cambridge classification to accommodate 
the additional information about pancreatic duct and parenchyma in classification of 
patients with CP (57).  
 
Figure 3-2: Measurements of the pancreatic gland volume (A) and main pancreatic 
duct (B) in a patient with chronic pancreatitis. Abbreviations: MPD: main pancreatic 
duct; CBD: common bile duct; D: duodenum; A: aorta; IVC: inferior vena cava. 
 
1.5.5. FIBROSIS IN PANCREATIC PARENCHYMA 
Diffusion weighted imaging (DWI) was obtained before and 1, 5, 9 and 13 minutes 
after secretin stimulation. For study I, pancreatic apparent diffusion coefficient (ADC) 
maps were generated by calculating the slope of the logarithmic decay curve for signal 
intensity against b-value (50 and 800 sec/mm2) with use of MRI software (Syngo, 
Siemens). For study II, the ADC maps were based on three b values (50, 400 and 800 
sec/mm2) and generated by commercially available software (AW server 2.0, General 
Electric, Milwaukee, Wisconsin, USA). Regions of interest (ROIs) were in both 
studies manually placed in the pancreatic head, body, and tail for measurement of 
ADC. 
1.5.6. FAT LEVEL IN PANCREATIC PARENCHYMA (ONLY STUDY II) 
Measurements of pancreatic fat signal fraction (FSF) was performed on LAVA-flex 
images (Dixon) obtained prior to secretin. Analyses was done in EazyViz, placing 
ROIs in the pancreatic head, body, and tail on both water-only and fat-only images. 
Same positions were used as in the DWI analysis. Mean signal intensity (SI) in the 
ROI’s was used to calculate FSF by the formula: FSF= SI fat only / (SI water only + 
SI fat only).   
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Additionally, for study II the analyses of ADC and FSF was only performed in 
subjects with pancreatic gland volume larger than 25 ml. The decision was made to 
accommodate enough pancreatic parenchyma for a ROI of 8 mm in diameter. The 
main pancreatic duct and cystic lesions were avoided when placing the ROIs, see 
Figure 3-3.  
 
Figure 3-3: Placement of regions of interest (red circle) for measurements of apparent 
diffusion coefficient (A) and fat signal fraction (B). 
1.5.7. EXOCRINE PANCREATIC FUNCTION 
Evaluation of exocrine pancreatic function with s-MRI was performed by analyzing 
coronal T2-weighted imaging (slice thickness 10 mm) obtained 10 and 4 minutes 
before and 1, 5, 9 and 13 minutes after secretin stimulation. As in previous studies, 
changes in signal intensity on T2-weighted images were used as a measure of changes 
in small bowel fluid volumes (40,44,58). Analyses was performed in the new semi-
automatic application developed in Matlab 2013b (Mathworks, Natick, MA, USA) for 
more automated (i.e., faster, more objective and quantitative) calculation of pancreatic 
fluid output, see Figure 1 in PhD paper II (59). The raw DICOM data was uploaded 
to the application and a rough ROI was manually drawn around duodenum and upper 
small bowel. The application automatically adjusted the ROI to only include regions 
with high signal intensity (high fluid content) within the small bowel and provides a 
fluid volume for each slice. By adding all slices the application automatically 
calculates the small bowel fluid volume for each time point. Pancreatic secretion for 
each time point is calculated by subtracting the fluid volume 4 minutes before secretin. 
Additionally, changes in pancreatic ADC 1, 5, 9 and 13 minutes after secretin 
stimulation were used as an indirect evaluation of exocrine pancreatic function. 
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Changes in ADC for each time point were calculated by subtracting the ADC obtained 
4 minutes before secretin administration.  
 
Figure 3-4: Segmentation of small bowel fluid volume in the new semi-automatic 
application for calculation of pancreatic secretion. Abbreviations: D: duodenum; SB: 
small bowel; ROI: regions of interest; SI: signal intensity  
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Fecal elastase was measured in all subject as this is the most routinely and clinically 
performed measure of exocrine pancreatic function at most centers worldwide. 
Commercially available kits were used in both study I (ScheBo Biotech, Giessen, 
Germany) and in study II (Pancreatic Elastase, ELISA, BIOSERV diagnostics GmbH, 
Rostock, Germany). Exocrine pancreatic insufficiency was defined as fecal elastase 
below 200 µg/g (60).  
In study I, the short endoscopic secretin test (EST) was used as golden standard for 
exocrine pancreatic function (27). The subject fasted for 8 hours and received both 
pharyngeal lidocaine spray (Xylocaine; AstraZeneca AB, Sweden) and conscious 
sedation with intravenous midazolam (Midazolam; Actavis Group HF, Iceland) 2-5 
mg before the procedure. Twenty-five minutes after intravenous secretin 
administration a duodenoscope was positioned in the stomach, and after luminal 
examination all gastric fluids all gastric fluids were aspirated and discarded. Thirty 
minutes after secretin stimulation the tip of the duodenoscope was positioned distally 
to the papilla of Vater and three samples of duodenal juice were collected, each 
sampling lasting for 5 minutes. The details of duodenal juice handling and analyses 
are thoroughly described in previous publications (17,27,29,61). EPI was defined as 
peak bicarbonate concentration below 80 mEq/L (14).  
1.5.8. CLINICAL CHARACTERISTICS IN CP 
Fecal elastase was measured by a commercially available kit and EPI was defined as 
fecal elastase below 200 µg/g (paper III) (62). When attending the annual follow-up 
in the outpatient setting, CP patients were classified according to M-ANNHEIM 
clinical staging (M-ANNHEIM 0: Stage of subclinical CP; M-ANNHEIM I: CP 
without pancreatic insufficiency; M-ANNHEIM II: CP with partial pancreatic 
insufficiency; M-ANNHEIM III: Painful CP with complete pancreatic insufficiency; 
M-ANNHEIM IV: Secondary painless CP (burnout)) (63). Duration of CP was from 
the date for the initial diagnosis till the date for the s-MRI scan. 
1.5.9. DISEASE BURDEN IN CP  
For study II, disease burden was characterized by hospitalization, quality of life (QOL) 
score and pain score. Patients with CP were prospectively followed during the 
observation period, which started from the date of the individual s-MRI examination 
(index date) and ended in august 2016. The time to first hospitalization or death from 
the index date, total number of hospitalizations and duration of hospitalizations was 
noted. When attending the annual follow-up examinations at the Centre for Pancreatic 
Disease, patients filled out questionnaires for evaluation of quality of life (QOL) and 
pain symptoms. The European organization for research and treatment of cancer 
quality of life questionnaire (EORTC QLQ-C30) was used to evaluate QOL (64,65). 
Pain scores were measured using the modified Brief Pain Inventory short form (m-
BPI-sf) (66).   
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1.5.10. STATISTICAL ANALYSES 
Different analyses approaches were used in study I and study II depending on the aims 
and the data construction. The statistical analyses of the studies are reported in details 
in paper II-IV. In general, the difference between continues variables were calculated 
using student’s t-test or two-sample Wilcoxon rank-sum test. Analyses of variances 
(ANOVA) was used to analyze differences in total secreted volumes and ADC values, 
with different time points (secreted volume 1, 5, 9 and 13 minutes after secretin) as a 
within-subject factor, and group (CP vs. HC and CF vs. HC) as a between subject 
factor. The potential confounding effects of age on s-MRI parameters were explored 
using linear regression models. Correlation analysis were performed using Pearson or 
Spearman´s correlation coefficients (r) as appropriate. P values <0.05 was considered 
statistically significant. The software package STATA version 14.2 (StataCorp LP, 
College Station, Texas) was used. 
CHARACTERIZATION OF PANCREATIC MORPHOLOGY AND FUNCTION WITH ADVANCED MRI 
 
31 
RESULTS 
The key results from the studies are presented in this chapter. More detailed results 
are reported in paper I-IV. An overview of the main results from paper II-IV is 
illustrated in Figure 4.1. 
 AIM I 
Aim: To investigate latest developments in s-MRI and the range of clinical application 
in the benign pancreatic disorders (paper I). 
Key results: 
• The literature review concludes that S-MRI is feasible in most benign 
pancreatic clinical scenarios and has the potential to aid in the identification 
of early main pancreatic duct changes and exocrine pancreatic dysfunction. 
• There is a great variation in the applied imaging protocols, image 
interpretation strategies, and consequently, the information that may be 
extracted from s-MRI. 
Interpretation: There is a need for standardization and evaluation of s-MRI protocols 
to exploit the full spectrum of morphological and functional changes that can be 
measured with s-MRI. 
 AIM II 
Aim: To evaluate our s-MRI protocol including a novel, semi-automatic application 
for assessment of exocrine pancreatic function against a “gold standard” endoscopic 
secretin test in patients with cystic fibrosis compared to healthy controls (paper II). 
Key results: 
• Pancreatic secretion measured at 9 and 13 minutes after secretin stimulation 
was reduced in CF patients with EPI compared to CF patients without EPI 
and HC (P = 0.035).  
• Pancreatic secretion at 13 minutes had an AUROC of 0.93 for prediction of 
EPI when compared to the endoscopic secretin test. It was the best 
performing s-MRI parameter and outperformed the fecal elastase test 
(AUROC of 0.84).  
• CF patients with EPI had lower baseline ADC values than patients without 
EPI and HC in the pancreatic head (P = 0.02) and body (P = 0.016). No 
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significant changes in ADC values were seen after secretin administration 
for any of the subgroups. 
Interpretation: Semi-automatic quantification of pancreatic secretion at 13 minutes 
post-secretin has high diagnostic accuracy for EPI in patients with CF. 
 AIM III 
Aim: To investigate pancreatic morphology and exocrine function with the novel s-
MRI protocol in patients with chronic pancreatitis compared to healthy controls 
(paper III). 
Key results: 
• Pancreatic gland volume was lower in CP patients as compared to HC (P < 
0.001).  
• Main pancreatic duct diameter was larger in CP patients as compared to HC 
(P < 0.001). 
• Patient with CP had lower baseline ADC values than the HC in the pancreatic 
head (P < 0.001) and body (P < 0.001). 
• CP patients had significantly higher FSF in the pancreatic body compared to 
HC (P = 0.002). 
• Following secretin stimulation, patients with CP had a significantly lower 
increase in ADC values from baseline to 1 min after secretin (ΔADC) 
compared to HC (head P < 0.001; body P < 0.001). 
• Pancreatic secretion at 9 minutes (P = 0.017) and 13 minutes (P = 0.003) 
after secretin administration was significantly lower in CP patients compared 
to HC. 
• Pancreatic gland volume had negative correlation with Cambridge 
classification (r = -0.26, P = 0.02) and baseline ADC (r = -0.35, P = 0.027), 
and positive correlation with ΔADC (r = 0.38, P = 0.015). 
Interpretation: Morphological and functional s-MRI parameters provide non-
invasive, detailed, and complementary information about the pathological processes 
involved in CP. However, the morphological and functional parameters are not well 
correlated, reflecting the complex nature of the disease.    
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 AIM IV 
Aim: To explore association between pancreatic morphological and functional s-MRI 
parameters, clinical characteristics, and disease burden in patients with chronic 
pancreatitis (paper III + IV). 
Key results: 
• The morphological and functional s-MRI parameters were comparable 
between patients with alcoholic and non-alcoholic etiology of CP (all P-
values > 0.12). 
• The disease duration of CP was negatively correlated to pancreatic gland 
volume (P < 0.001) and fecal elastase (P = 0.05).  
• Pancreatic gland volume was higher in M-ANNHEIM clinical stage I 
compared to II (P = 0.001) as well as in M-ANNHEIM clinical stage I 
compared to stage III & IV (polled together) (P < 0.001).  
• Large pancreatic gland volume was associated with high fecal elastase values 
(r=0.66, P = 0.0016). 
• The Cambridge classification was associated with M-ANNHEIM clinical 
staging (P = 0.033). 
• A main pancreatic duct diameter below 5 mm was associated with reduced 
time to first hospitalization (HR 2.06, P = 0.043). 
• Pancreatic secretion at 13 minutes after secretin administration was 
positively correlated with QOL (P = 0.0072) and negatively correlated with 
pain interference score (P = 0.032).  
• Morphological and functional s-MRI parameters were not related to pain 
intensity score (all P > 0.07).  
Interpretation: Morphological and functional information derived from s-MRI are 
relevant clinical biomarkers that in the future could aid in understanding the 
mechanisms underlying symptoms and the different stages in the development of CP, 
in monitoring disease progress, and optimizing treatment of CP.   
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Figure 4-1: Overview of the main results from paper II-IV. Abbreviations: CP: 
chronic pancreatitis; CF: cystic fibrosis; HC: healthy controls; EPI: exocrine 
pancreatic insufficiency; ADC: apparent diffusion coefficient; FSF: fat signal 
fraction; QOL: quality of life; AUROC: area under receiver operating characteristics 
curve; >/<: larger/lower; ↑: high/increased; ↓: low/decreased     
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DISCUSSION 
Advanced MRI with secretin-stimulation was used to characterize pancreatic 
morphology and exocrine function in patients with CP. The discussion will focus on 
s-MRI parameters ability to differentiate between patients with CP and HC, the 
relation to clinical characteristics and disease burden in CP, and technical 
considerations of the methods used.   
 PANCREATIC GLAND VOLUME 
Evaluation of pancreatic gland volume has been performed on CT since 1980 with 
measurements of anterior-posterior diameter in the pancreatic head, body and tail (67). 
Several studies have reported age and sex-related decrease in pancreatic size in adults 
without known pancreatic disease (see Paper I) (67,68). When adjusting for age, we 
found that patients with CP had a significantly lower pancreatic gland volume 
compared to sex-matched HC (see Paper III). Pancreatic atrophy is a widely accepted 
common feature of CP, however the Cambridge classification categorizes 
enlargement of pancreas as a diagnostic criteria for CP (2,57). Additionally, recent 
study of pancreatic size with US based on anterior-posterior diameter reported that 
CP patients had a marginally larger gland compared to HC but they conclude that the 
value in diagnosis of CP is questionable (69). There are several differences compared 
to our study; the diagnostic criteria for CP, duration of the disease among CP patients 
was larger in our study and we excluded all patients with suspected acute exacerbation 
of CP. Furthermore, pancreatic gland volume in our study was the volume of the 
pancreatic parenchyma as we excluded main pancreatic duct and all cystic lesions. 
Time needed for analyses was reduced using a new, semi-automatic application.  
Additionally, we found that duration of CP was negatively correlated to gland volume 
(see Paper III). Our study confirms that pancreatic atrophy is a feature of CP that is 
associated to duration of the disease. More studies with volume segmentation in 
patients with suspected/mild CP are needed to evaluate the value of gland volume 
measurements in diagnosis of CP.    
 MAIN PANCREATIC DUCT & CAMBRIDGE 
CLASSIFICATION 
Main pancreatic duct distortion in CP and the classification according to Cambridge 
system has been well-established since 1984 (56). Studies have also confirmed that 
MPD size varies according to age, sex and location in the pancreas (head, body and 
tail) (see Paper I) (70). Thus, adjusting for age in a sex-matched study population, we 
could report that patients with CP had a significantly wider maximal main pancreatic 
duct diameter compared to HC (see Paper III, table 2). Measurements were performed 
on 3D MRCP prior to secretin-stimulation. In clinical settings, especially in patients 
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with suspected or mild CP, dynamic MRCP after secretin-stimulation is preferred as 
it increases visibility and enables assessment of duct dynamics (see Paper I, Table 1). 
However, with our explorative study design we focused on evaluation of exocrine 
pancreatic function after secretin-stimulation leaving no time for dynamic MRCP for 
duct evaluation.  
Main pancreatic duct diameter was not associated with any of the other s-MRI 
parameters. However, higher Cambridge classification score was associated with 
reduced pancreatic gland volume (see Paper III, table 3). These findings suggest that 
change in pancreatic duct caliber alone seems insufficient as a diagnostic criterion in 
CP, and that the Cambridge classification, which includes other pathological features 
i.e. cysts, irregular parenchymal structure, and calcification alongside dilatation of 
main duct dilatation and side branches, could be a more valuable parameter for the 
diagnosis of CP (see Paper III). 
 
 PARENCHYMAL FIBROSIS 
In line with several other studies, patients with CP had lower ADC values (before 
secretin stimulation) compared to HC reflecting fibrosis in the pancreatic parenchyma 
(49,71). When adjusting for age, the fibrotic changes were only present in the 
pancreatic head and body (see Paper III, table 2) (72). It is important to measure ADC 
in the different anatomical regions of pancreas as studies in healthy have confirmed 
that ADC differs significantly from the pancreatic head, body and tail (73). 
Additionally, the ADC is an artificial parameter, without any true intrinsic relevance 
or histological correlate, that combines both diffusion and perfusion characteristics 
(74). The impact of diffusion and perfusion properties on the ADC value of the tissue 
is determined by the b values; the higher b values have stronger diffusion weighting 
and weaker perfusion weighting, whereas the lower b values have stronger perfusion 
weighting and lower diffusion weighting (see Paper I). It has been reported that 
alcoholic chronic pancreatitis is associated with both tissue fibrosis and reduction of 
blood vessel density on histological examination (48,75). Multiple b values (50, 400 
and 800) used in our study enable a more precise calculation of ADC with less 
perfusion contamination (76). Additionally, several papers have reported good 
correlation between DWI imaging and fibrosis in histological specimens in both 
pancreas and liver (53,77). Our study supports that DWI is a valuable, non-invasive 
method for quantification of what is considered to be fibrotic changes of the pancreas 
in CP.  Furthermore, baseline ADC values were negatively correlated with pancreatic 
gland volumes suggesting that parenchymal fibrotic changes accompany the gradual 
pancreatic atrophy. However, there was no association between parenchymal fibrosis, 
EPI and Cambridge classification as previously reported (78). 
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 PARENCHYMAL FAT LEVEL 
Mean FSF values in the pancreatic body were significantly higher in patients with CP 
compared to HC (see Paper III, table II). Surprisingly, the changes were not present 
in the pancreatic head and tail. A recent study from Yoon et al. in 2016 reported a 
moderate correlation with estimated fat fraction on Dixon imaging compared to fat 
amount in histological specimens after pancreatectomy (53). In addition, Tirkes et al. 
in 2016 reported that mean FSF in patients with mild CP was significantly higher 
compared to HC (79). Our results provide supporting evidence for the rising number 
of studies on quantification of pancreatic fatty infiltrations with advanced MRI 
(80,81). In our study, FSF in the pancreatic body did no correlate to any other s-MRI 
parameter, clinical characteristics, or disease burden. Especially our non-existing 
correlation between FSF and ADC indicates that development of fibrosis and fatty 
infiltration might be two separate pathological processes of the CP disease. Currently, 
the role of fatty infiltration in development and progression of CP is still largely 
unknown and more studies are needed.        
 EXOCRINE PANCREATIC FUNCTION 
Mild to moderate EPI, with vague clinical symptoms, is present in several diseases 
and could be a relevant marker for early (asymptomatic) stages of CP but remains 
challenging to diagnose. Matos et al. 1997 proposed a s-MRI based semi-quantitative 
visual assessment of pancreatic secretion (see Figure 5-1) and several publications 
followed proposing different quantitative techniques for estimating pancreatic output 
in milliliters as a quantitative volume (36,58,82,83). They were all based on the 
assumption that changes in signal intensity on T2-weighted imaging can be used to 
assess changes in liquid containing volumes in a region of interest (see Paper I) (83). 
We evaluated pancreatic secretion  with a new, semi-automatic application using 
coronal T2-weighted images, 7-8 slices with thickness of 10 mm, that had shown good 
correlation with EST in characterizing pancreatic exocrine function in healthy 
controls (44). In contrast, most studies use dynamic 2D MRCP for semi-quantitative 
visual and quantitative assessment of EPI as it also allows more dynamic assessment 
of the main pancreatic duct (see Discussion, subsection Main pancreatic duct & 
Cambridge classification) (40,58).   
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Figure 5-1: Semi-quantitative visual assessment of pancreatic exocrine function after 
secretin-stimulation, figure from Schneider et al. 2006 (84). a: antrum ventriculi; db: 
duodenal bulb; pd: main pancreatic duct; pap: papilla of Vater; Grade 0-3.   
In patients with CF (Study I, Paper II), we could demonstrate that pancreatic secretion 
13 minutes after secretin-stimulation had a high diagnostic accuracy for EPI when 
compared with the “gold standard” EST. Furthermore, pancreatic secretion performed 
better than the fecal elastase test (Paper II, Table 4). This supports the assumption that 
our protocol settings and the new semi-automatic application for calculation of 
pancreatic secretion are valid and a precise tool for assessment of EPI. In CF, a small 
portion of patients develops EPI later in life and need regular follow up. For these 
patients, s-MRI could provide a precise and non-invasive test comparable with EST 
for diagnosing EPI. However, the majority of CF patients develop EPI early in life 
and fecal elastase is a well-described and reliable tool for diagnosis and follow-up of 
EPI (85,86). 
In patients with CP (Study II, Paper III), pancreatic secretin at 9 and 13 minutes after 
secretin-stimulation was significantly lower when compared to HC. Thus, pancreatic 
secretion at 1 and 5 minutes after secretin was similar. Mensel et al. performed a large 
s-SMI study in 819 healthy subjects and could report that the highest pancreatic flow 
output (11.7 ml/min) was observed 9 min after secretin. Our results indicate that 
patient with CP have a decline in their secretory capacity after 5 min compared to HC 
which could reflect the loss of pancreatic parenchyma. However, pancreatic secretion 
was not associated with pancreatic gland volume or any of the other s-MRI parameters 
(Paper III, Table 3). Another potential explanation could be that secretin also 
stimulated biliary secretin of water and bicarbonate alongside gastric secretion in 
duodenum that blurs the initial “true pancreatic secretin”(15). Currently, we are not 
able to fully explain the secretory profile in patients with CP but our study confirms 
that pancreatic secretion is significantly hampered compared to the HC. However, 
pancreatic secretion is a complex parameter that seems unaffected by pancreatic 
atrophy, duct distortion, fibrotic changes, and fatty infiltrations. Our results are 
obtained from a population of CP patients where the majority had morphologically 
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marked CP changes (54% of CP patient classified with Cambridge score IV, see Paper 
III, Table 2). This contradicts the general assumption that pancreatic morphology and 
function are more related in the advanced stages of CP. In conclusion, increasing 
number of papers have reported that s-MRI can be used to diagnose EPI. The 
challenge remains to provide a more standardized s-MRI protocol so that larger 
studies can be performed in CP which could help in reporting some cut-off values for 
normal vs. pathological pancreatic secretion, and thereby potentially help detecting 
mild/early CP.           
Additionally, CP patients had a significantly lower increase in ADC from baseline to 
1 min after secretin stimulation compared to HC. This indicates that measuring ADC 
could detect CP and maybe EPI after secretin stimulation. However, previous studies 
in post-secretin ADC have reported inconclusive results. Erturk et al. reported that 
patients with CP had a later peak (median 7 min) in ADC compared to HC (median 2 
min) (48). We did not observe any such peak in ADC in patients with CP, baseline 
ADC and post-secretin ADC at all timepoint were similar (Figure 2, Paper III). Akisik 
et al. reported that mean pre-secretin and maximum post-secretin ADC was higher in 
HC compared to CP, but the percentage increase ADC and time to peak ADC did not 
differ between the groups (87). However, their healthy population also had the highest 
increase in ADC between baseline and 2 minutes after secretin stimulation. Different 
imaging protocols and definition of CP preclude direct comparison of the results. 
However, HC did have a steep increase in ADC in all three studies approximately 
between baseline and 2 min after secretin, the reports on CP are somewhat 
inconsistent. If we assume that pancreatic secretion is the same at 1 min after secretin, 
then the reason for increase in ADC in HC could be due to increased blood flow that 
is hampered in patients with CP.  However, our choice of multiple b-values in 
calculation of ADC reduces the impact of perfusion. Therefore, it can be argued that 
the increase in ADC is due to higher ductal and acinar secretion in the pancreatic 
parenchyma in HC. Currently, the role of ADC measurements after secretin 
stimulation remains unclear and further studies in larger populations are required.      
 S-MRI & CLINICAL CHARACTERISTICS 
More severe M-ANNHEIM clinical stage and low fecal elastase were associated with 
loss of pancreatic parenchyma (pancreatic gland volume) and higher Cambridge 
classification score, see Figure 5-2. M-ANNHEIM clinical stage and fecal elastase 
were mutually correlated, however as EPI is included in M-ANNHEIM classification 
this result was expected. Additionally, low pancreatic gland volume was associated 
with longer disease duration. 
The clinical value of measuring pancreatic gland volume has, to our best knowledge, 
not previously been reported. Our findings indicate that presence of multiple common 
features in CP (exocrine and endocrine dysfunction, pain, duct distortion) and longer 
disease duration is accompanied with loss of pancreatic parenchyma (Figure 5-2). A 
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potential explanation for the importance of pancreatic volume loss could be that 
multiple parallel pathological processes co-exists (main duct distortion, side branch 
pathology, cystic lesions, parenchymal fibrosis, and fatty infiltration) which over time 
leads to destruction and loss of pancreatic parenchyma as the ultimate end result, 
and during the process results in functional insufficiency. This is further supported 
with the association of M-ANNHEIM clinical stage, gland volume and the modified 
Cambridge classification. Consequently, our results indicate that monitoring 
pancreatic volume and/or Cambridge classification in CP could provide valuable 
information about disease progression. The Cambridge scoring is performed on MRI 
without the need for secretion stimulation, expensive software programs and could be 
easily integrated in daily radiological routine. 
 
Interestingly, fecal elastase and pancreatic secretion were not correlated as reported 
in previous studies (18,88). This suggest that functional loss of ductal cell (reflected 
in reduced pancreatic secretion) and acinar cell (reflected in low fecal elastase) does 
not necessarily coexist, and may occur at different stages of the disease. This 
highlights the complexity of EPI in patients with CP and that pancreatic fluid secretion 
only uncovers some aspects of the exocrine problem. MRI is not able measure 
concentrations of enzymes used for digestion as possible with EST, however 
diagnostic accuracy for EPI is similar as reported in patients with CF. Thus, s-MRI 
for evaluation of EPI is a valid tool and could be of great value in patients with 
suspected EPI where fecal elastase has a documented low sensibility.  
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Figure 5-2: Overview of associations between s-MRI parameters, clinical 
characteristics, and disease burden in chronic pancreatitis (CP) (study II). Dashed 
lines represent a significant (P<0.05) association.  
 S-MRI & DISEASE BURDEN IN CP 
A main pancreatic duct diameter < 5 mm was associated with a shorter time to first 
CP related hospitalization, see Figure 5-2. None of the other s-MRI parameters were 
associated with hospitalization frequency and duration. This indicates that patients 
with less severe duct dilatation are more prone to earlier hospitalization compared to 
patients with more severe duct distortion. In a recent study from Olesen et al., pain 
was identified as the most frequent cause for hospitalization followed by common bile 
duct stenosis, symptomatic pseudocysts and acute in chronic pancreatitis (9). The 
reason for hospitalization is not identified in our study, but patients with smaller duct 
diameter could have more preserved parenchyma and hence be more prone to 
developing painful clinical situations like acute inflammation, pseudocysts, or 
significant duct obstruction. However, main pancreatic duct diameter was not 
associated with pancreatic gland volume nor with pain intensity score. Nevertheless, 
this is an interesting finding and suggests that MRI could be used in identifying 
patients at risk.  
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Low pancreatic secretion and low fecal elastase were associated with reduced QOL, 
which could be explained by that patients with preserved pancreatic function may 
have lower risk of malnutrition and associated complications such as sarcopenia and 
osteoporosis, which all lead to higher QOL. Previous papers have reported that low 
body weight in patients with CP was associated with poor health status (89). However, 
Olesen et al. have previously reported that exocrine insufficiency was not related to 
QOL in a multivariate analysis including pain symptoms, diabetes and different 
pancreatic and extrapancreatic complications (90). Patients with CP have a decreased 
QOL compared to general population and especially pain has been identified as the 
main cause for this (5,90). However, our results show that QOL in context of CP could 
be determined by numerous factors and their intricate interaction in the individual 
patient. Additionally, reduced pancreatic secretion was associated with higher pain 
interference score, which is calculated by parameters such as activity, mood, working 
capacity and sleep. Consequently, pain interference could also be affected by exocrine 
malfunction and malnutrition rather than pain itself.  
 
None of the morphological and functional s-MRI parameters were associated with 
pain intensity score. Our results are in line with the emerging evidence suggesting that 
inflammation and fibrotic changes of pancreatic parenchyma leads to alternations in 
function and morphology of intrapancreatic nerves, which subsequently results in 
development of persistent pain in CP with sensitization of the central nervous system 
(i.e. neurogenic pain) (91,92). Hence, pancreatic morphology and function has no 
direct relation to persistent pain in chronic pancreatitis patients with more 
established/long-lasting disease (71) 
 
 STUDY LIMITATIONS 
There are study limitations in both study I and study II.  
The study population in study I was relatively small which could affect the power of 
statistical analyses. Additionally, time interval between s-MRI and EST was no 
predefined and varied from subject to subject, see Table 1, Paper II. In study II, the 
ADC and FSF analyses was performed only in patients with pancreatic gland larger 
than 25 ml to accommodate a ROI of 8 mm in diameter. Though, this resulted in a 
much smaller sample size (only 38-44 of 83 patients) for these parameters. 
Furthermore, MRI is not able detect calcifications in the pancreatic parenchyma 
meaning that ROIs could contain different amounts of calcifications. Theoretically, 
this would result in lower ADC values and probably higher FSF values in patients 
with CP. Currently, we are not able to estimate if this had an impact on our ADC and 
FSF results. Furthermore, our CP patients had quite severe disease stages of CP, 
hence, extrapolation of our results to early disease and identifying early disease 
markers is difficult.  
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The s-MRI protocol and the new semi-automatic application for quantification of 
pancreatic secretion were validated against the “gold standard” EST in patients with 
CF for estimation of EPI. After displaying high diagnostic accuracy for EPI, the same 
concept was used in patients with CP. However, the genetics and pathogenesis of CF 
are well described and similar in most patients resulting in a very homogenous 
population. In contrast, the pathogenesis of CP is more complex and yet not fully 
understood resulting in more heterogenous population. This means that patients with 
CP probably have more complicated pathways for developing EPI compared to CF. 
The consequence could be that the very high diagnostic accuracy of our models for 
EPI in CF cannot be expected in patients with CP.  
 CLINICAL & FUTURE PERSPECTIVES 
MRI is a currently the preferred imaging method for more advanced assessment of the 
pancreatic gland in benign disorders. However, the lack of systematic approach and 
little use of quantitative measures in reporting radiological findings leave much room 
for improvement. Several morphological and functional s-MRI parameters presented 
in this thesis could be integrated in the daily routines to aid the clinicians in the 
diagnosis and follow-up in patients with CP. The staging according to the modified 
Cambridge classification is after some practice easily performed without any need for 
expensive software programs. Evaluation of the pancreatic gland volume and 
pancreatic secretion require additional software and time for post-processing and 
analyses. But as our Study I and Study II demonstrate, pancreatic secretion as an 
estimate for EPI with high diagnostic accuracy only require of two image series 
(before and 13 minutes after secretin-stimulation). This significantly reduces the time 
needed for post-analyses, and will also enable to perform a regular MRCP with 
dynamic assessment of the main pancreatic duct after secretin stimulation. 
Measurement of fibrosis (ADC) and fatty infiltrations are promising parenchymal 
parameters, but further exploration is needed to assess their implications in natural 
history and progression of CP. In general, more and faster automatization of the 
analyses is the key for quicker implementation of the s-MRI parameters in the clinical 
daily routine. Furthermore, as presented in Paper I, there is also a need for 
harmonization and standardization of s-MRI protocols to enable more reliable 
comparison of the results from different studies, and to pave the road for initiation of 
multicenter studies. Optimization of the s-MRI protocol and the obtained results could 
also be of value in other diseases like acute pancreatitis, pancreatic cystic neoplasm 
and sphincter of Oddi dysfunction (Paper I).    
Several other MRI methods for assessing pancreatic parenchyma are currently gaining 
more interest. Tirkes et al. reported that T1 relaxation time in the pancreatic 
parenchyma (referred to as the T1-mapping method) was significantly increased in 
patients with mild CP compared to the control group (79). T1 mapping is also showing 
promising results in detailed tissue characterization in cardiac MRI (including 
identification of myocardial scaring) so further improvement within this area can be 
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expected. Sugita et al. reported that optimized arterial spin-labeling techniques can be 
used for directs visualization of pancreatic juice flow (93), and is hence a potential 
method for exocrine secretory assessment without the use of secretin stimulation. MRI 
elastography for measurement of changes in mechanical properties (tissue stiffness) 
associated with fibrosis and more advanced DWI techniques like Intra-Voxel 
Incoherent Motion diffusion imaging (assessment of both the perfusion and diffusion 
component of DWI) are currently being tested in liver (94,95). A potential 
breakthrough in these areas could also be used for characterization of the pancreatic 
parenchyma. Magnetic resonance spectroscopy has also been used in liver imaging, 
and, with improvement of the scanner technique, it could lead to assessment of 
metabolites of the pancreas(96). The ability to provide a morphological and functional 
assessment of a specific organ in one examination is the future of MRI. Therefore, as 
the optimal goal, we aim to provide an advanced MRI protocol for detailed 
characterization of morphological and functional pancreatic parameters to improve 
diagnosis, follow-up and treatment of patients with CP. 
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CONCLUSION 
The literature review identified numerous advanced MRI parameters for 
characterization of the pancreatic gland. In this thesis, morphological s-MRI 
parameters included pancreatic atrophy (gland volume), main pancreatic duct 
diameter, fibrosis (ADC), fatty infiltrations (FSF) and the modified Cambridge 
classifications score. The exocrine pancreatic function was estimated with 
assessment of pancreatic secretory volumes and changes in ADC before and after 
secretin-stimulation.   
The pancreatic secretion 13 minutes after secretin had high diagnostic accuracy for 
EPI when compared to the “gold standard” EST in patients with CF. Thus, the 
method and the new semi-automatic application are considered valid, non-invasive 
tools for assessment of EPI. All the morphological and functional s-MRI parameters 
could differentiate between patients with CF and HC. In patients with CP, lower 
pancreatic gland volume was associated with higher Cambridge classification score 
and lower ADC reflecting increased fibrotic changes. These results are in line with 
the assumption that s-MRI can provide a detailed, non-invasive characterization of 
the pancreatic parenchyma which can be used to detect pathological features in 
patients with CP. In addition, a low association between morphological and 
functional features in CP was demonstrated. Pancreatic gland volume was lower and 
the Cambridge classification score higher with more severe M-ANNHEIM clinical 
staging. Additionally, higher pancreatic secretion 13 minutes after secretin was 
associated with QOL and large pancreatic gland was associated with high fecal 
elastase test. These results indicate that several pathophysiological processes likely 
are involved at the same time during the complex CP disease course, and that our s-
MRI parameters provide information on the different disease features that can be 
used as relevant clinical biomarkers in diagnosing and grading disease severity in 
patients with CP. 
The overall results in this thesis show that several common pathological features of 
CP can be detected with present advanced MRI techniques. Thus, s-MRI parameters 
can be used for diagnosis, monitoring disease progress and in the future likely be used 
for more efficient follow-up and treatment of patients with CP. 
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